The DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.
Mir-34: A New Weapon Against Cancer?
Open accessAbstract
The microRNA(miRNA)-34a is a key regulator of tumor suppression. It controls the expression of a plethora of target proteins involved in cell cycle, differentiation and apoptosis, and antagonizes processes that are necessary for basic cancer cell viability as well as cancer stemness, metastasis, and chemoresistance. In this review, we focus on the molecular mechanisms of miR-34a-mediated tumor suppression, giving emphasis on the main miR-34a targets, as well as on the principal regulators involved in the modulation of this miRNA. Moreover, we shed light on the miR-34a role in modulating responsiveness to chemotherapy and on the phytonutrients-mediated regulation of miR-34a expression and activity in cancer cells. Given the broad anti-oncogenic activity of miR-34a, we also discuss the substantial benefits of a new therapeutic concept based on nanotechnology delivery of miRNA mimics. In fact, the replacement of oncosuppressor miRNAs provides an effective strategy against tumor heterogeneity and the selective RNA-based delivery systems seems to be an excellent platform for a safe and effective targeting of the tumor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
RETRACTED: Downregulation of miR‐122 in the rodent and human hepatocellular carcinomas
Kutay, H., Bai, S., Datta, J., Motiwala, T., Pogribny, I., Frankel, W., Jacob, S. T., & Ghoshal, K. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20982 · Cited by 608
RetractedRETRACTED: Maturation of MicroRNA Is Hormonally Regulated by a Nuclear Receptor
Yamagata, K., Fujiyama, S., Ito, S., Ueda, T., Murata, T., Naitou, M., Takeyama, K.-I., Minami, Y., O'Malley, B. W., & Kato, S. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.08.017 · Cited by 197
RetractedMaturation of MicroRNA Is Hormonally Regulated by a Nuclear Receptor
Yamagata, K., Fujiyama, S., Ito, S., Ueda, T., Murata, T., Naitou, M., Takeyama, K., Minami, Y., O’Malley, B. W., & Kato, S. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.02.011 · Cited by 71
RetractedMicroRNA expression profiles classify human cancers
Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B. L., Mak, R. H., Ferrando, A. A., et al. (2005) · Nature · doi:10.1038/nature03702 · Cited by 9,539
MicroRNA signatures in human cancers
Calin, G. A., & Croce, C. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1997 · Cited by 7,590
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Oncomirs—MicroRNAs with a role in cancer
Esquela-Kerscher, A., & Slack, F. J. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1840 · Cited by 5,884
A microRNA expression signature of human solid tumors defines cancer gene targets
Volinia, S., Calin, G. A., Liu, C.-G., Ambs, S., Cimmino, A., Petrocca, F., Visone, R., Iorio, M., Roldo, C., Ferracin, M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510565103 · Cited by 5,697
Calin, G. A., Dumitru, C. D., Shimizu, M., Bichi, R., Zupo, S., Noch, E., Aldler, H., Rattan, S., Keating, M., Rai, K., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242606799 · Cited by 5,111
The Versatile Role of microRNA-30a in Human Cancer
Wang, C., Yang, X., Chen, Y., & Chen, L. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000471111 · Cited by 3,409
Causes and consequences of microRNA dysregulation in cancer
Croce, C. M. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2634 · Cited by 2,998
Toxicity of cationic lipids and cationic polymers in gene delivery
Lv, H., Zhang, S., Wang, B., Cui, S., & Yan, J. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.04.014 · Cited by 2,286
Targeting microRNAs in cancer: rationale, strategies and challenges
Garzon, R., Marcucci, G., & Croce, C. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3179 · Cited by 1,493
MicroRNAs and other non-coding RNAs as targets for anticancer drug development
Ling, H., Fabbri, M., & Calin, G. A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4140 · Cited by 1,465
Therapeutic microRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model
Kota, J., Chivukula, R. R., O'Donnell, K. A., Wentzel, E. A., Montgomery, C. L., Hwang, H.-W., Chang, T.-C., Vivekanandan, P., Torbenson, M., Clark, K. R., et al. (2009) · Cell · doi:10.1016/j.cell.2009.04.021 · Cited by 1,452
The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44
Liu, C., Kelnar, K., Liu, B., Chen, X., Calhoun-Davis, T., Li, H., Patrawala, L., Yan, H., Jeter, C., Honorio, S., et al. (2011) · Nature Medicine · doi:10.1038/nm.2284 · Cited by 1,400
SMAD proteins control DROSHA-mediated microRNA maturation
Davis, B. N., Hilyard, A. C., Lagna, G., & Hata, A. (2008) · Nature · doi:10.1038/nature07086 · Cited by 1,244
The miR-34 family in cancer and apoptosis
Hermeking, H. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.56 · Cited by 1,236
Tazawa, H., Tsuchiya, N., Izumiya, M., & Nakagama, H. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707351104 · Cited by 903
Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer
Lodygin, D., Tarasov, V., Epanchintsev, A., Berking, C., Knyazeva, T., Körner, H., Knyazev, P., Diebold, J., & Hermeking, H. (2008) · Cell Cycle · doi:10.4161/cc.7.16.6533 · Cited by 784
IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis
Rokavec, M., Öner, M. G., Li, H., Jackstadt, R., Jiang, L., Lodygin, D., Kaller, M., Horst, D., Ziegler, P. K., Schwitalla, S., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73531 · Cited by 753
miR-34 – a microRNA replacement therapy is headed to the clinic
Bader, A. G. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00120 · Cited by 728
miR-221 overexpression contributes to liver tumorigenesis
Pineau, P., Volinia, S., McJunkin, K., Marchio, A., Battiston, C., Terris, B., Mazzaferro, V., Lowe, S. W., Croce, C. M., & Dejean, A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907904107 · Cited by 699
Tabernero, J., Shapiro, G. I., LoRusso, P. M., Cervantes, A., Schwartz, G. K., Weiss, G. J., Paz-Ares, L., Cho, D. C., Infante, J. R., Alsina, M., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0429 · Cited by 698
Development of a Lung Cancer Therapeutic Based on the Tumor Suppressor MicroRNA-34
Wiggins, J. F., Ruffino, L., Kelnar, K., Omotola, M., Patrawala, L., Brown, D., & Bader, A. G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0655 · Cited by 677
Trang, P., Wiggins, J. F., Daige, C. L., Cho, C., Omotola, M., Brown, D., Weidhaas, J. B., Bader, A. G., & Slack, F. J. (2011) · Molecular Therapy · doi:10.1038/mt.2011.48 · Cited by 667
MicroRNA-34a Inhibits Glioblastoma Growth by Targeting Multiple Oncogenes
Li, Y., Guessous, F., Zhang, Y., DiPierro, C., Kefas, B., Johnson, E., Marcinkiewicz, L., Jiang, J., Yang, Y., Schmittgen, T. D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0529 · Cited by 614
miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions
Siemens, H., Jackstadt, R., Hünten, S., Kaller, M., Menssen, A., Götz, U., & Hermeking, H. (2011) · Cell Cycle · doi:10.4161/cc.10.24.18552 · Cited by 609
Toyota, M., Suzuki, H., Sasaki, Y., Maruyama, R., Imai, K., Shinomura, Y., & Tokino, T. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0325 · Cited by 600
Yang, P., Li, Q.-J., Feng, Y., Zhang, Y., Markowitz, G. J., Ning, S., Deng, Y., Zhao, J., Jiang, S., Yuan, Y., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.07.023 · Cited by 536
Nanoparticles Modified With Tumor-targeting scFv Deliver siRNA and miRNA for Cancer Therapy
Chen, Y., Zhu, X., Zhang, X., Liu, B., & Huang, L. (2010) · Molecular Therapy · doi:10.1038/mt.2010.136 · Cited by 515
Deng, X., Cao, M., Zhang, J., Hu, K., Yin, Z., Zhou, Z., Xiao, X., Yang, Y., Sheng, W., Wu, Y., et al. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.02.006 · Cited by 511
MiR-34, SIRT1, and p53: The feedback loop
Yamakuchi, M., & Lowenstein, C. J. (2009) · Cell Cycle · doi:10.4161/cc.8.5.7753 · Cited by 468
McManus, M. T. (2003) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(03)00038-5 · Cited by 439
Li, N., Fu, H., Tie, Y., Hu, Z., Kong, W., Wu, Y., & Zheng, X. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.09.035 · Cited by 418
A microRNA miR-34a-Regulated Bimodal Switch Targets Notch in Colon Cancer Stem Cells
Bu, P., Chen, K.-Y., Chen, J. H., Wang, L., Walters, J., Shin, Y. J., Goerger, J. P., Sun, J., Witherspoon, M., Rakhilin, N., et al. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2013.03.002 · Cited by 357
miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer
Gallardo, E., Navarro, A., Viñolas, N., Marrades, R. M., Diaz, T., Gel, B., Quera, A., Bandres, E., Garcia-Foncillas, J., Ramirez, J., et al. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp219 · Cited by 342
Li, L., Yuan, L., Luo, J., Gao, J., Guo, J., & Xie, X. (2013) · Clinical and Experimental Medicine · doi:10.1007/s10238-012-0186-5 · Cited by 314
Frequent Downregulation of miR-34 Family in Human Ovarian Cancers
Corney, D. C., Hwang, C.-I., Matoso, A., Vogt, M., Flesken-Nikitin, A., Godwin, A. K., Kamat, A. A., Sood, A. K., Ellenson, L. H., Hermeking, H., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2642 · Cited by 308
microRNA-34a is tumor suppressive in brain tumors and glioma stem cells
Guessous, F., Zhang, Y., Kofman, A., Catania, A., Li, Y., Schiff, D., Purow, B., & Abounader, R. (2010) · Cell Cycle · doi:10.4161/cc.9.6.10987 · Cited by 306
A positive feedback between p53 and miR-34 miRNAs mediates tumor suppression
Okada, N., Lin, C.-P., Ribeiro, M. C., Biton, A., Lai, G., He, X., Bu, P., Vogel, H., Jablons, D. M., Keller, A. C., et al. (2014) · Genes & Development · doi:10.1101/gad.233585.113 · Cited by 297
Pramanik, D., Campbell, N. R., Karikari, C., Chivukula, R., Kent, O. A., Mendell, J. T., & Maitra, A. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0152 · Cited by 296
DNA methylation and microRNA dysregulation in cancer
Suzuki, H., Maruyama, R., Yamamoto, E., & Kai, M. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.07.007 · Cited by 271
Genistein Inhibits Prostate Cancer Cell Growth by Targeting miR-34a and Oncogenic HOTAIR
Chiyomaru, T., Yamamura, S., Fukuhara, S., Yoshino, H., Kinoshita, T., Majid, S., Saini, S., Chang, I., Tanaka, Y., Enokida, H., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070372 · Cited by 266
Nalls, D., Tang, S.-N., Rodova, M., Srivastava, R. K., & Shankar, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024099 · Cited by 256
Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer
Mudduluru, G., Ceppi, P., Kumarswamy, R., Scagliotti, G. V., Papotti, M., & Allgayer, H. (2011) · Oncogene · doi:10.1038/onc.2011.13 · Cited by 252
Kasinski, A. L., & Slack, F. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2001 · Cited by 242
Pang, R. T. K., Leung, C. O. N., Ye, T.-M., Liu, W., Chiu, P. C. N., Lam, K. K. W., Lee, K.-F., & Yeung, W. S. B. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq066 · Cited by 242
Di Martino, M. T., Leone, E., Amodio, N., Foresta, U., Lionetti, M., Pitari, M. R., Cantafio, M. E. G., Gullà, A., Conforti, F., Morelli, E., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1708 · Cited by 239
Self-citationTivnan, A., Orr, W. S., Gubala, V., Nooney, R., Williams, D. E., McDonagh, C., Prenter, S., Harvey, H., Domingo-Fernández, R., Bray, I. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038129 · Cited by 233
Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth
Leone, E., Morelli, E., Di Martino, M. T., Amodio, N., Foresta, U., Gullà, A., Rossi, M., Neri, A., Giordano, A., Munshi, N. C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3325 · Cited by 219
Self-citationKojima, K., Fujita, Y., Nozawa, Y., Deguchi, T., & Ito, M. (2010) · The Prostate · doi:10.1002/pros.21185 · Cited by 205
Kaller, M., Liffers, S.-T., Oeljeklaus, S., Kuhlmann, K., Röh, S., Hoffmann, R., Warscheid, B., & Hermeking, H. (2011) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.010462 · Cited by 201
Rothe, K., Lin, H., Lin, K. B. L., Leung, A., Wang, H. M., Malekesmaeili, M., Brinkman, R. R., Forrest, D. L., Gorski, S. M., & Jiang, X. (2014) · Blood · doi:10.1182/blood-2013-07-516807 · Cited by 199
Yan, K., Gao, J., Yang, T., Ma, Q., Qiu, X., Fan, Q., & Ma, B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033778 · Cited by 195
Eichelser, C., Flesch-Janys, D., Chang-Claude, J., Pantel, K., & Schwarzenbach, H. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2013.205161 · Cited by 195
Recent Developments in Nanoparticle-Based siRNA Delivery for Cancer Therapy
Lee, J.-M., Yoon, T.-J., & Cho, Y.-S. (2013) · BioMed Research International · doi:10.1155/2013/782041 · Cited by 190
Kang, J., Kim, E., Kim, W., Seong, K. M., Youn, H., Kim, J. W., Kim, J., & Youn, B. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.490482 · Cited by 188
Heinemann, A., Zhao, F., Pechlivanis, S., Eberle, J., Steinle, A., Diederichs, S., Schadendorf, D., & Paschen, A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1977 · Cited by 187
Rossi, M., Pitari, M. R., Amodio, N., Di Martino, M. T., Conforti, F., Leone, E., Botta, C., Paolino, F. M., Del Giudice, T., Iuliano, E., et al. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24306 · Cited by 185
Self-citationAkao, Y., Noguchi, S., Iio, A., Kojima, K., Takagi, T., & Naoe, T. (2011) · Cancer Letters · doi:10.1016/j.canlet.2010.10.006 · Cited by 181
Witwer, K. W., Sisk, J. M., Gama, L., & Clements, J. E. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902712 · Cited by 181
de Antonellis, P., Medaglia, C., Cusanelli, E., Andolfo, I., Liguori, L., De Vita, G., Carotenuto, M., Bello, A., Formiggini, F., Galeone, A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024584 · Cited by 171
Self-citationCraig, V. J., Cogliatti, S. B., Imig, J., Renner, C., Neuenschwander, S., Rehrauer, H., Schlapbach, R., Dirnhofer, S., Tzankov, A., & Müller, A. (2011) · Blood · doi:10.1182/blood-2010-10-312231 · Cited by 166
Yang, F., Li, Q.-J., Gong, Z.-B., Zhou, L., You, N., Wang, S., Li, X.-L., Li, J.-J., An, J.-Z., Wang, D.-S., et al. (2014) · Technology in Cancer Research & Treatment · doi:10.7785/tcrt.2012.500364 · Cited by 163
Nakatani, F., Ferracin, M., Manara, M. C., Ventura, S., Monaco, V. D., Ferrari, S., Alberghini, M., Grilli, A., Knuutila, S., Schaefer, K., et al. (2011) · The Journal of Pathology · doi:10.1002/path.3007 · Cited by 162
ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression
Ahn, Y., Gibbons, D. L., Chakravarti, D., Creighton, C. J., Rizvi, Z. H., Adams, H. P., Pertsemlidis, A., Gregory, P. A., Wright, J. A., Goodall, G. J., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63608 · Cited by 162
Amodio, N., Di Martino, M. T., Foresta, U., Leone, E., Lionetti, M., Leotta, M., Gullà, A. M., Pitari, M. R., Conforti, F., Rossi, M., et al. (2012) · Cell Death & Disease · doi:10.1038/cddis.2012.175 · Cited by 158
Self-citationYamamura, S., Saini, S., Majid, S., Hirata, H., Ueno, K., Deng, G., & Dahiya, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029722 · Cited by 155
DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma
Amodio, N., Leotta, M., Bellizzi, D., Martino, M. T. D., D’Aquila, P., Lionetti, M., Fabiani, F., Leone, E., Gullà, A., Passarino, G., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.675 · Cited by 153
Self-citationExpression of miR-34 is lost in colon cancer which can be re-expressed by a novel agent CDF
Roy, S., Levi, E., Majumdar, A. P. N., & Sarkar, F. H. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-58 · Cited by 151
In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma
Martino, M. T. D., Gullà, A., Cantafio, M. E. G., Lionetti, M., Leone, E., Amodio, N., Guzzi, P. H., Foresta, U., Conforti, F. S., Cannataro, M., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.820 · Cited by 145
Self-citationSiemens, H., Neumann, J. H. L., Jackstadt, R., Mansmann, U., Horst, D. A., Kirchner, T., & Hermeking, H. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1703 · Cited by 144
Kumar, B., Yadav, A., Lang, J. C., Teknos, T. N., & Kumar, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037601 · Cited by 141
Siemens, H., Jackstadt, R., Kaller, M., & Hermeking, H. (2013) · Oncotarget · doi:10.18632/oncotarget.1202 · Cited by 140
Xia, J., Duan, Q., Ahmad, A., et al. (2012) · Current Drug Targets · doi:10.2174/138945012804545597 · Cited by 140
Silber, J., Skanderup, A. J., Ozawa, T., Harinath, G., Pedraza, A. M., Sander, C., Holland, E. C., & Huse, J. T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033844 · Cited by 130
The Therapeutic Potential of MicroRNAs in Cancer
Thorsen, S. B., Obad, S., Jensen, N. F., Stenvang, J., & Kauppinen, S. (2012) · Cancer Journal · doi:10.1097/ppo.0b013e318258b5d6 · Cited by 127
miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme
Yin, D., Ogawa, S., Kawamata, N., Leiter, A., Ham, M., Li, D., Doan, N., SAID, J. W., Black, K. L., & Koeffler, H. P. (2012) · Oncogene · doi:10.1038/onc.2012.132 · Cited by 125
Garofalo, M., Jeon, Y.-J., Nuovo, G. J., Middleton, J. D., Secchiero, P., Joshi, P., Alder, H., Nazaryan, N., Leva, G. D., Romano, G., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067581 · Cited by 123
Martino, M. T. D., Campani, V., Misso, G., Cantafio, M. E. G., Gullà, A., Foresta, U., Guzzi, P. H., Castellano, M., Grimaldi, A., Gigantino, V., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090005 · Cited by 122
Self-citationDang, Y., Luo, D., Rong, M., & Chen, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061054 · Cited by 121
Franchina, T., Amodeo, V., Bronte, G., Savio, G., Ricciardi, G. R. R., Picciotto, M., Russo, A. D., Giordano, A., & Adamo, V. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24422 · Cited by 118
Hu, Q., Jiang, Q., Jin, X., Shen, J., Wang, K., Li, Y. B., Xu, F., Tang, G., & Li, Z. H. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2012.12.016 · Cited by 116
Mackiewicz, M., Huppi, K. E., Pitt, J. J., Dorsey, T. H., Ambs, S., & Caplen, N. J. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1690-0 · Cited by 115
Vinall, R., Ripoll, A., Wang, S., Pan, C., & White, R. D. D. (2011) · International Journal of Cancer · doi:10.1002/ijc.26256 · Cited by 110
Guo, J., Li, W., Shi, H., Xie, X., Li, L., Tang, H., Wu, M., Kong, Y., Yang, L., Gao, J., et al. (2013) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-013-1723-6 · Cited by 109
Calimeri, T., Battista, E., Conforti, F. S., Neri, P. E., Martino, M. T. D., Rossi, M., Foresta, U., Piro, E., Ferrara, F., Amorosi, A., et al. (2011) · Leukemia · doi:10.1038/leu.2010.300 · Cited by 105
Self-citationImpaired DICER1 function promotes stemness and metastasis in colon cancer
Iliou, M. S., da Silva-Diz, V., Carmona, F. J., Ramalho-Carvalho, J., Heyn, H., Villanueva, A., Muñoz, P., & Esteller, M. (2013) · Oncogene · doi:10.1038/onc.2013.398 · Cited by 104
MicroRNA-34a Modulates Chemosensitivity of Breast Cancer Cells to Adriamycin by Targeting Notch1
Li, X., Ji, M., Zhong, S., Zha, Q.-B., Xu, J., Zhao, J., & Tang, J. (2012) · Archives of Medical Research · doi:10.1016/j.arcmed.2012.09.007 · Cited by 103
Leotta, M., Biamonte, L., Raimondi, L., Ronchetti, D., Martino, M. T. D., Botta, C., Leone, E., Pitari, M. R., Neri, A., Giordano, A., et al. (2014) · Journal of Cellular Physiology · doi:10.1002/jcp.24669 · Cited by 102
Self-citationPeurala, H., Greco, D., Heikkinen, T., Kaur, S., Bártková, J., Jamshidi, M., Aittomäki, K., Heikkilä, P., Bartek, J., Blomqvist, C., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026122 · Cited by 101
Amodio, N., Bellizzi, D., Leotta, M., Raimondi, L., Biamonte, L., D’Aquila, P., Martino, M. T. D., Calimeri, T., Rossi, M., Lionetti, M., et al. (2013) · Cell Cycle · doi:10.4161/cc.26585 · Cited by 100
Self-citationShen, Z.-S., Zhan, G., Ye, D., Ren, Y., Cheng, L.-X., Wu, Z.-H., & Guo, J. (2012) · Medical Oncology · doi:10.1007/s12032-011-0156-x · Cited by 99
Li, L., Xie, X., Luo, J., Liu, M., Xi, S., Guo, J., Kong, Y., Wu, M., Gao, J., Zeming, X., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.201 · Cited by 98
MicroRNA-608 and MicroRNA-34a Regulate Chordoma Malignancy by Targeting EGFR, Bcl-xL and MET
Zhang, Y., Schiff, D., Park, D. M., & Abounader, R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091546 · Cited by 98
Ji, X., Wang, Z., Geamanu, A., Goja, A., Sarkar, F. H., & Gupta, S. V. (2012) · International Journal of Cancer · doi:10.1002/ijc.27549 · Cited by 98
Raimondi, L., Amodio, N., Martino, M. T. D., Altomare, E., Leotta, M., Caracciolo, D., Gullà, A., Neri, A., Taverna, S., D’Aquila, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1747 · Cited by 94
Self-citationBiological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia
Lionetti, M., Musto, P., Martino, M. T. D., Fabris, S., Agnelli, L., Todoerti, K., Tuana, G., Mosca, L., Cantafio, M. E. G., Grieco, V., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2043 · Cited by 94
Self-citationMicroRNA-34a Modulates MDM4 Expression via a Target Site in the Open Reading Frame
Mandke, P., Wyatt, N., Fraser, J., Bates, B., Berberich, S. J., & Markey, M. P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042034 · Cited by 92
Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma
Tagliaferri, P., Rossi, M., Martino, M. T. D., Amodio, N., Leone, E., Gullà, A., Neri, A., & Tassone, P. (2012) · Current Cancer Drug Targets · doi:10.2174/156800912802429355 · Cited by 89
Self-citationCirculating miR‐34a levels are reduced in colorectal cancer
Nugent, M., Miller, N., & Kerin, M. J. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.23174 · Cited by 88
miR-34a regulates cisplatin-induce gastric cancer cell death by modulating PI3K/AKT/survivin pathway
Cao, W., Yang, W., Fan, R., Li, H., Jiang, J., Geng, M., Jin, Y., & Wu, Y. (2013) · Tumor Biology · doi:10.1007/s13277-013-1171-7 · Cited by 87
MicroRNA-34a Inhibits Human Osteosarcoma Proliferation by Downregulating Ether à go-go 1 Expression
Wu, X., Zhong, D., Gao, Q. Q., Zhai, W., Ding, Z., & Wu, J. (2013) · International Journal of Medical Sciences · doi:10.7150/ijms.5528 · Cited by 86
Type I Interferons in the Treatment of Pancreatic Cancer
Vitale, G., van Eijck, C. H. J., Ing, P. M. V. K., Erdmann, J. I., Speel, E. M., van der Wansem, K., Mooij, D. M., Colao, A., Lombardi, G., Croze, E., et al. (2007) · Annals of Surgery · doi:10.1097/01.sla.0000261460.07110.f2 · Cited by 85
Active Targeting Strategies for Anticancer Drug Nanocarriers
Basile, L., Pignatello, R., & Passirani, C. (2012) · Current Drug Delivery · doi:10.2174/156720112800389089 · Cited by 85
Inactivation of AR and Notch-1 signaling by miR-34a attenuates prostate cancer aggressiveness.
Kashat, M. A., Azzouz, L., Sarkar, S., Kong, D., Li, Y., & Sarkar, F. H. (2012) · Europe PMC (PubMed Central) · Cited by 83
Lou, W., Chen, Q., Ma, L., Liu, J., Yang, Z., Shen, J., Cui, Y., Bian, X., & Qian, C. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0985-x · Cited by 82
Vitale, G., Zappavigna, S., Marra, M., Dicitore, A., Meschini, S., Condello, M., Arancia, G., Castiglioni, S., Maroni, P., Bendinelli, P., et al. (2012) · Biotechnology Advances · doi:10.1016/j.biotechadv.2011.08.001 · Cited by 82
Self-citationNon-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma
Amodio, N., Martino, M. T. D., Neri, A., Tagliaferri, P., & Tassone, P. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.796356 · Cited by 81
Self-citationMicroRNAs and Cancer; an Overview
Tutar, L., Tutar, E., & Tutar, Y. (2014) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201015666140519095304 · Cited by 79
Wang, S., Cao, M., Deng, X., Xiao, X., Yin, Z., Hu, Q., Zhou, Z., Zhang, F., Zhang, R., Wu, Y. F., et al. (2014) · Advanced Healthcare Materials · doi:10.1002/adhm.201400222 · Cited by 78
The oncogenic RNA-binding protein Musashi1 is regulated by tumor suppressor miRNAs
Vo, D. T., Qiao, M., Smith, A. D., Burns, S. C., Brenner, A. J., & Penalva, L. O. F. (2011) · RNA Biology · doi:10.4161/rna.8.5.16041 · Cited by 72
In-Depth Analysis Shows Synergy between Erlotinib and miR-34a
Zhao, J. Y., Kelnar, K., & Bader, A. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089105 · Cited by 71
Jin, K., Xiang, Y., Tang, J., Wu, G., Li, J., Xiao, H., Li, C., Chen, Y., & Zhao, J. (2013) · Tumor Biology · doi:10.1007/s13277-013-1207-z · Cited by 67
Chakrabarti, M., Ai, W., Banik, N. L., & Ray, S. K. (2012) · Neurochemical Research · doi:10.1007/s11064-012-0936-5 · Cited by 67
17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation
Dijkstra, M. K., van Lom, K., Tielemans, D., Elstrodt, F., Langerak, A. W., Veer, M. B. V., & Jongen‐Lavrencic, M. (2008) · Leukemia · doi:10.1038/leu.2008.264 · Cited by 63
TP53-independent Function of miR-34a via HDAC1 and p21CIP1/WAF1
Zhao, J. Y., Lammers, P., Torrance, C. J., & Bader, A. G. (2013) · Molecular Therapy · doi:10.1038/mt.2013.148 · Cited by 62
Menges, C. W., Kadariya, Y., Altomare, D. A., Talarchek, J. N., Neumann-Domer, E., Wu, Y., Xiao, G., Shapiro, I. M., Kolev, V. N., Pachter, J. A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-2062 · Cited by 59
Duan, W., Xu, Y., Dong, Y., Cao, L., Tong, J., & Zhou, X. (2013) · Journal of Radiation Research · doi:10.1093/jrr/rrs136 · Cited by 58
Scognamiglio, I., Martino, M. T. D., Campani, V., Virgilio, A., Galeone, A., Gullà, A., Cantafio, M. E. G., Misso, G., Tagliaferri, P., Tassone, P., et al. (2014) · BioMed Research International · doi:10.1155/2014/217365 · Cited by 57
Self-citationNegrini, M., Cutrona, G., Bassi, C., Fabris, S., Zagatti, B., Colombo, M., Ferracin, M., D’Abundo, L., Saccenti, E., Matis, S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2497 · Cited by 57
Self-citationJaveri, A., Ghaffarpour, M., Taha, M. F., & Houshmand, M. (2013) · Medical Oncology · doi:10.1007/s12032-012-0413-7 · Cited by 56
Rolfo, C. D., Fanale, D., Hong, D. S., Tsimberidou, A. M., Piha-Paul, S. A., Pauwels, P., van Meerbeeck, J. P., Caruso, S., Bazan, V., Cicero, G., et al. (2014) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201015666140519123219 · Cited by 56
Hui, C., Fu, Y., Lijia, Y., Yi, L., Hongxia, X., Zhou, Y. G., Jundong, Z., Zhang, Q., & Mi, M. (2012) · Breast Cancer Research · doi:10.1186/bcr3194 · Cited by 53
Dicitore, A., Caraglia, M., Gaudenzi, G., Manfredi, G. I., Amato, B., Mari, D., Persani, L., Arra, C., & Vitale, G. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.11.003 · Cited by 52
Self-citationmicroRNA-34a Sensitizes Lung Cancer Cell Lines to DDP Treatment Independent of p53 Status
Wang, X., Dong, K., Gao, P., Long, M., Fang, L., Weng, Y., Ouyang, Y., Ren, J.-H., & Zhang, H. (2012) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2012.1218 · Cited by 51
Rücker, F. G., Russ, A. C., Cocciardi, S., Kett, H., Schlenk, R. F., Botzenhardt, U., Langer, C., Krauter, J., Fröhling, S., Schlegelberger, B., et al. (2012) · Leukemia · doi:10.1038/leu.2012.208 · Cited by 50
microRNA-34a promotes DNA damage and mitotic catastrophe
Kofman, A. V., Kim, J., Park, S., Dupart, E., Letson, C. S., Bao, Y., Ding, K., Chen, Q., Schiff, D., Larner, J. M., et al. (2013) · Cell Cycle · doi:10.4161/cc.26459 · Cited by 50
Ma, Y., Bao-Han, W., Lv, X., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072383 · Cited by 49
MiR-34a is up-regulated in response to low dose, low energy X-ray induced DNA damage in breast cells
Stankevicins, L., da Silva, A. P. A., dos Passos, F. V., Ferreira, E. D. S., Ribeiro, M. C. M., David, M., Pires, E. J., Ferreira-Machado, S. C., Vassetzky, Y. S., de Almeida, C. E., et al. (2013) · Radiation Oncology · doi:10.1186/1748-717x-8-231 · Cited by 49
Aberrant micro RNA expression in multiple myeloma
Dimopoulos, K., Gimsing, P., & Grønbæk, K. (2013) · European Journal Of Haematology · doi:10.1111/ejh.12124 · Cited by 48
MicroRNA-34a Suppresses Cell Proliferation by Targeting LMTK3 in Human Breast Cancer MCF-7 Cell Line
Zhao, G.-Q., Guo, J., Li, D., Jia, C., Yin, W., Sun, R., Lv, Z., & Cong, X. (2013) · DNA and Cell Biology · doi:10.1089/dna.2013.2130 · Cited by 48
Tassone, P., Neri, P. E., Burger, R., Martino, M. T. D., Leone, E., Amodio, N., Caraglia, M., & Tagliaferri, P. (2012) · Current Cancer Drug Targets · doi:10.2174/156800912802429292 · Cited by 45
Self-citationMuppala, S., Mudduluru, G., Leupold, J. H., Buergy, D., Sleeman, J. P., & Allgayer, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059563 · Cited by 44
Early Targets of miR-34a in Neuroblastoma
Antonellis, P. D., Carotenuto, M., Vandenbussche, J., Vita, G. D., Ferrucci, V., Medaglia, C., Boffa, I., Galiero, A., Somma, S. D., Magliulo, D., et al. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m113.035808 · Cited by 42
A p53-inducible microRNA-34a downregulates Ras signaling by targeting IMPDH
Kim, H.-R., Roe, J., Lee, J., Hwang, I., Cho, E., & Youn, H. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.01.077 · Cited by 41
Li, Z., Branham, W. S., Dial, S. L., Wang, Y., Guo, L., Shi, L. M., & Chen, T. (2010) · BMC Genomics · doi:10.1186/1471-2164-11-609 · Cited by 40
CD95 Is Part of a Let-7/p53/miR-34 Regulatory Network
Hau, A., Ceppi, P., & Peter, M. E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049636 · Cited by 36
Clinical implications of microRNAs in cancer
Bovell, L. C., Putcha, B. D. K., Samuel, T., & Manne, U. (2013) · Biotechnic & Histochemistry · doi:10.3109/10520295.2013.788735 · Cited by 20
Oligonucleotide delivery in cancer therapy
Rosa, G. D., Stefano, D. D., & Galeone, A. (2010) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2010.527942 · Cited by 19
miR-34a is essential for p19Arf-driven cell cycle arrest
Iqbal, N. S., Mei, J., Liu, J., & Skapek, S. X. (2014) · Cell Cycle · doi:10.4161/cc.27725 · Cited by 17
Creating a flexible multiple microRNA expression vector by linking precursor microRNAs
Qiu, X., Friedman, J. M., & Liang, G. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.06.123 · Cited by 11
Tomosugi, M., Sowa, Y., Yasuda, S., Tanaka, R., Riele, H. T., Ikawa, H., Koyama, M., & Sakai, T. (2012) · Cancer Science · doi:10.1111/cas.12012 · Cited by 11
Cited by
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
Rupaimoole, R., & Slack, F. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.246 · Cited by 4,741
MicroRNA as Biomarkers and Diagnostics
Wang, J., Chen, J., & Sen, S. (2016) · Journal of Cellular Physiology · doi:10.1002/jcp.25056 · Cited by 793
Xiang, Y., Guo, Z., Zhu, P., Chen, J., & Huang, Y. (2019) · Cancer Medicine · doi:10.1002/cam4.2108 · Cited by 752
Targeting noncoding RNAs in disease
Adams, B. D., Parsons, C., Walker, L., Zhang, W. C., & Slack, F. J. (2017) · Journal of Clinical Investigation · doi:10.1172/jci84424 · Cited by 673
MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer
Zhang, L., Liao, Y., & Tang, L. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1059-5 · Cited by 510
Metadata
- Authors
- Misso, G., Di Martino, M. T., De Rosa, G., Farooqi, A. A., Lombardi, A., Campani, V., Zarone, M. R., Gullà, A., Tagliaferri, P., Tassone, P., & Caraglia, M.
- Venue
- Molecular Therapy - Nucleic Acids
- Publisher
- Elsevier BV
- Published
- 2014-01
- Volume
- 3
- Pages
- e195
- ISSN
- 2162-2531 (ISSN-L)
- OpenAlex
- W2045604306
- Cited by
- 498
- References
- 144
- FWCI
- 18.47
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.